Invesco Pharmaceuticals ETF

PJP

Market cap $309M

The price cuts will save Medicare billions of dollars in prescription-drug spending.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on June 23, 2005.

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.

Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund launched on 06/23/2005.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.

This article provides a top-down view of the healthcare sector based on valuation, quality and momentum. The healthcare providers and pharmaceuticals/biotechnology subsectors show good value scores. The Invesco Pharmaceuticals ETF has outperformed the pharma industry benchmark XPH and the broader healthcare ETF XLV since 2006.